Prevalence, 12-Month Prognosis, and Clinical Management Need of Depression in Coronary Heart Disease Patients: A Prospective Cohort Study by Kuhlmann, Stella L. et al.
Regular Article
Psychother Psychosom 2019;88:300–311
Prevalence, 12-Month Prognosis, and Clinical 
Management Need of Depression in Coronary 
Heart Disease Patients: A Prospective Cohort 
Study
Stella L. Kuhlmann a, b    Volker Arolt c    Wilhelm Haverkamp d    Peter Martus e    
Andreas Ströhle f    Johannes Waltenberger g    Nina Rieckmann a    
Jacqueline Müller-Nordhorn a    
a
 Institute of Public Health, Charité – Universitätsmedizin Berlin, corporate member of the Freie Universität Berlin, 
Humboldt-Universität zu Berlin, and the Berlin Institute of Health, Berlin, Germany; b Division of Emergency and 
Acute Medicine (CVK, CCM), Charité – Universitätsmedizin Berlin, corporate member of the Freie Universität 
Berlin, Humboldt-Universität zu Berlin, and the Berlin Institute of Health, Berlin, Germany; c Department of 
Psychiatry, University of Münster, Münster, Germany; d Department of Internal Medicine and Cardiology, Charité – 
Universitätsmedizin Berlin, corporate member of the Freie Universität Berlin, Humboldt-Universität zu Berlin, and 
the Berlin Institute of Health, Berlin, Germany; e Department of Clinical Epidemiology and Applied Biostatistics, 
Eberhard-Karls-Universität Tübingen, Tübingen, Germany; f Department of Psychiatry and Psychotherapy,  
Charité – Universitätsmedizin Berlin, corporate member of the Freie Universität Berlin, Humboldt-Universität zu 
Berlin, and the Berlin Institute of Health, Berlin, Germany; g Department of Cardiovascular Medicine, University 
Hospital Münster, Münster, Germany
Received: February 28, 2019
Accepted: June 10, 2019
Published online: August 26, 2019
Stella L. Kuhlmann
Institute of Public Health, Charité – Universitätsmedizin Berlin
Seestrasse 73
DE–13347 Berlin (Germany)
E-Mail stella.kuhlmann @ charite.de





Depression · Coronary heart disease · Treatment ·  
Prognosis · Clinical management need
Abstract
Background: Screening for depression in patients with coro-
nary heart disease (CHD) remains controversial. There is lim-
ited data on the actual depression management need in rou-
tine care. The aim of this study was to examine the preva-
lence, treatment rates, prognosis, and management need of 
clinical and subclinical depression in CHD patients according 
to the American Heart Association recommendations and 
the National Institute for Health and Care Excellence (NICE) 
guideline “Depression in Adults with a Chronic Physical 
Health Problem”. Methods: Patients were recruited at 2 Ger-
man university clinics between 2012 and 2014. Depressive 
disorders were assessed according to the DSM-IV and de-
pressive symptom severity at baseline and during follow-up 
was evaluated with the Patient Health Questionnaire (PHQ-
9). Depression management need was determined by the 
severity and longitudinal course of depression symptoms. 
Results: Of 1,024 patients (19% women), 12% had clinical 
depression (depressive disorder) and 45% had subclinical 
depression (PHQ-9 score ≥5) at baseline. Among those with 
clinical depression, 46% were in treatment at least once dur-
Nina Rieckmann and Jacqueline Müller-Nordhorn contributed equal-
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ing 12 months; 26% were continuously in treatment during 
follow-up. Depressive disorder and depressive symptoms 
were significant risk factor-adjusted predictors of the 
12-months mortality (adjusted HR = 3.19; 95% CI 1.32–7.69, 
and adjusted HR = 1.09; 95% CI 1.02–1.16, respectively). De-
pressive symptoms persisted in 85% of the clinically de-
pressed and in 47% of the subclinically depressed patients. 
According to current recommendations, 29% of all CHD pa-
tients would require depression management within 1 year. 
Conclusions: There is a need for enhanced recognition, re-
ferral, and continuous and improved clinical management of 
depression in CHD patients. © 2019 S. Karger AG, Basel
Introduction
The US Preventive Services Task Force (USPSTF) rec-
ommends screening for depression in all adults [1]. Pa-
tients with coronary heart disease (CHD) are at an in-
creased risk for depressive disorders as well as subclinical 
elevated depressive symptoms [2]. Clinical and subclini-
cal depression in patients with CHD and other cardiac 
conditions are associated with an increased risk of car-
diac events and mortality [3, 4] and increased healthcare 
costs [5]. There is a controversial debate about screening 
for depression in these patients, since to date, evidence 
that screening improves cardiac and/or depression out-
comes is lacking [6]. However, there is recent evidence 
that screening including patient feedback on screening 
results might improve depression outcomes [7]. Depres-
sion is widely acknowledged as a risk factor. Next to the 
prognostic and economic importance, affected patients 
have a decreased health-related quality of life and show 
significantly less adherence to secondary prevention 
measures [8–10]. Short screening instruments for de-
pression exist and may be used to identify vulnerable pa-
tients [11] and to address the burden of depression re-
gardless of cardiac consequences [12]. Ten years ago, the 
American Heart Association (AHA) issued a recommen-
dation for screening, referral and treatment of depres-
sion in CHD patients [13]. The collaborative stepped 
care approach for the management of depression that is 
outlined in these recommendations is similar to the Na-
tional Institute for Health and Care Excellence (NICE) 
guideline for “Depression in Adults with a Chronic Phys-
ical Health Problem” [14]. Both recommend routine de-
pression screening in the context of somatic healthcare, 
referral to mental health care professionals in case of pos-
itive screening results, repeated screening in patients 
with subclinical symptoms, and continuous monitoring 
of patients once treatment has been initiated (online 
suppl. Fig. 1a, b; for all online suppl. material, see www. 
karger.com/doi/10.1159/000501502). Importantly, both 
recommendations are not based on a clinical depression 
diagnosis but rather on the severity and persistence of 
depressive symptoms, such as persistent sadness, loss of 
interest or pleasure in previously rewarding or enjoyable 
activities, and loss of energy, as well as a range of other 
cognitive-affective and somatic symptoms. Depression 
management options range from low-dose psychological 
and psychosocial interventions (e.g., education, lifestyle 
counseling, and behavioral activation) to psychotherapy, 
antidepressant medication, and other psychiatric treat-
ments and depend on patient preferences, symptom se-
verity, the psychiatric history, side effects, and the treat-
ment response [15]. Although these recommendations 
are frequently cited, epidemiological data on actual treat-
ment rates and the longitudinal course of depression in 
real-world clinical practice among CHD patients is 
scarce.
The aims of the current study were: (1) to examine the 
prevalence, treatment rates, and prognosis of clinical and 
subclinical depression in patients with CHD after a car-
diac-related hospitalization; (2) to identify predictors of 
persistent depressive symptoms, and (3) to quantify the 
need for depression management in these patients ac-
cording to the AHA recommendations [13] and the Na-
tional Institute for Health and Care Excellence (NICE) 
clinical guideline “Depression in Adults with a Chronic 
Physical Health Problem” [14]. Clinical depression refers 
to the diagnosis of a depressive disorder and subclinical 
depression comprises self-reported depressive symptoms 
at an elevated level using a standard depression screening 
tool.
Methods
Study Design and Population
The current study was part of CDCare (Depression Care for 
Hospitalized Coronary Heart Disease Patients), a prospective co-
hort study. Patients were recruited during a hospital stay at the 
cardiology units of 2 German university clinics (Universitätsklini-
kum Münster and Charité – Universitätsmedizin Berlin). Between 
July 2012 and July 2014, medical charts (n = 9,170) were consecu-
tively screened; 3,093 patients were assessed for eligibility and 
1,265 were eligible and gave written consent (online suppl. Fig. 2). 
To be included, patients had to have a chart-documented CHD 
diagnosis. Exclusion criteria were cognitive impairment, unavail-
ability for follow-up, terminal illness, or insufficient language pro-
ficiency. 
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Upon enrollment, patients completed a questionnaire and were 
administered a clinical psychiatric interview either at the clinic or 
via telephone within 8 weeks (the mean [±SD] time to completion 
was 12.9 ± 11.9 days) [16], which was completed by 1,024 patients. 
Follow-up questionnaires were mailed to patients after 6 and 12 
months, and 837 patients completed both follow-ups.
Clinical and Subclinical Depression
The presence of a depressive disorder according to the Diag-
nostic and Statistical Manual of Mental Disorders, Fourth Edition 
(DSM-IV) was determined using a standardized diagnostic inter-
view (Composite International Diagnostic Interview; CIDI) [17] 
which was conducted at baseline. Current diagnoses of dysthymia 
and major depressive disorder (MDD) were obtained. The pres-
ence of either or both diagnoses was categorized as “clinical de-
pression”.
The severity of depressive symptoms was assessed at 3 time 
points (baseline, 6-month follow-up, and 12-month follow-up) 
using the self-rated Patient Health Questionnaire (PHQ-9). The 
PHQ-9 is a brief, validated depression screening tool with scores 
ranging from 0 to 27. Scores of 0–4 indicate no depressive symp-
toms, scores of 5–9 indicate mild or subthreshold depressive 
symptoms, and scores ≥10 indicate moderate to severe depres-
sive symptoms [18]. Patients with a score ≥5 and no depressive 
disorder diagnosis were categorized as having “subclinical de-
pression”.
Depression Treatment
Depression treatment was assessed at all time points. At each 
assessment, the patients indicated whether they were currently re-
ceiving depression treatment (psychotherapy and/or antidepres-
sant medication). Antidepressant medication was additionally ex-
tracted by review of the medical charts (baseline) and from the list 
of medications that the patients provided (follow-up assessments). 
Vital Status
Deaths reported by family members or general practice physi-
cians were verified through the local death registries. For patients 
who were lost to follow-up and could not be contacted, an active 
search was conducted in the medical records of the study hospitals 
as well as through the local death registries. In 3 cases, the vital 
status could not be ascertained.
Predictors
Sociodemographic data (age, sex, partner status, and educa-
tion) as well as smoking were assessed at baseline. A history of any 
depressive disorder and a history of any anxiety disorder were as-
sessed in the clinical interview. Clinical variables were extracted 
from medical charts of the index hospitalization and included 
presence of an acute coronary syndrome (ACS), percutaneous cor-
onary intervention, left ventricular ejection fraction (LVEF), and 
medical comorbidities. The Charlson Comorbidity Index (CCI) 
[19] was computed in a modified version (exclusion of cardiac di-
agnoses and dementia). 
Statistical Analyses
Prevalence, Treatment Rates, and Prognosis of Depression
The prevalence of clinical and subclinical depression, treat-
ment rates at baseline and at the 2 follow-ups, and the longitudinal 
course of depressive symptoms are reported descriptively. 
Cox regression analyses were applied to analyze associations 
between the diagnosis of clinical depression (any depressive disor-
der) and depressive severity (PHQ-9 score) and mortality with ad-
justment for age, sex, LVEF, CCI, ACS at baseline, percutaneous 
coronary intervention at baseline, and smoking status.
Predictors of Persistent Depressive Symptoms over Time
Binary logistic regression models were used to identify predictors 
of depression persistence across 12 months among patients with ini-
tially elevated depressive symptoms (subclinical depression). Since 
only 5 patients were in remission among patients with an initial clin-
ical diagnosis of depression, no regression analyses were conducted in 
this group. In addition, we employed binary logistic regression mod-
els among initially nondepressed patients to identify predictors of in-
cident depressive symptoms which persisted at 6 and 12 months. The 
following predictors were preselected and entered simultaneously 
into the models: age, sex, ACS, antidepressant treatment, somatic co-
morbidity (CCI), LVEF, and baseline PHQ-9 score, as well as history 
of any depressive disorder or anxiety disorder. Due to low sample 
sizes within the subgroups, CCI (0 vs. 1 or more) and LVEF (preserved 
vs. mid-range or reduced) were dichotomized. Regression-based mul-
tiple imputation was conducted to deal with missing data on the PHQ, 
LVEF, and the CCI (SPSS module for multiple imputation).
Definition of Depression Management Need
Steps of depression care and depression management need 
were determined according to the AHA recommendation [13] and 
the NICE guideline [14] (online suppl. Fig. 1a, b). Both take into 
account the severity and course of depressive symptoms. 
The following depression groups were defined: no depressive 
symptoms (no clinical diagnosis and PHQ-9 < 5 at all time points), 
incident depressive symptoms (no clinical diagnosis and PHQ-9 
of 0–4 at baseline and PHQ-9 ≥5 at both follow-ups), remitting 
depressive symptoms (PHQ-9 ≥5 and/or clinical depression diag-
nosis at baseline and PHQ-9 < 5 at both follow-ups), and persistent 
depressive symptoms (PHQ-9 ≥5 and/or clinical depression diag-
nosis at baseline and PHQ-9 ≥5 at both follow-ups). Intermittent 
depressive symptoms were defined as a score of ≥5 at only 1 fol-
low-up assessment.
Patients in need for depression management across the 1-year 
study period were defined as those with persistent depressive symp-
toms at both follow-up time points, comprising the groups “persis-
tent depressive symptoms” and “incident depressive symptoms”.
Analyses were performed using IBM SPSS version 24. A two-
sided p < 0.05 was considered statistically significant.
Results
Study Sample
The characteristics of the study population are displayed 
in Table 1. The patients were divided into the following 3 
groups at baseline based on their initial depression status: 
patients with clinical depression according to the DSM-IV, 
patients without a depressive disorder but with elevated de-
pressive symptoms (subclinical depression), and patients 
without any signs of depression (online suppl. Fig. 2). 
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n = 123 (12%) n = 463 (45.2%) n = 438 (42.8%) n = 1,024
Sociodemographic variables
Age, years 59.8±10 62.6±10 63.5±10.3 0.002i, j 62.7±10.2
Females 36 (29.3) 91 (19.7) 70 (16) 0.004i 197 (19.2)
Education ≥12 yearsb 35 (28.5) 156 (35.1) 157 (36.5) 0.253 348 (34.9)
Living with a partnerc 80 (65) 355 (77.9) 371 (85.1) <0.001h, i, j 806 (79.4)
Medical variables
Current ACS 54 (43.9) 173 (37.4) 187 (42.7) 414 (40.4)
Unstable angina pectoris 19 (15.4) 52 (11.2) 44 (10) 0.081 115 (11.2)
Non-ST elevation myocardial infarction 20 (16.3) 75 (16.2) 71 (16.2) 166 (16.2)
ST elevation myocardial infarction 15 (12.2) 46 (9.9) 72 (16.4) 133 (13)
LVEF, n (%)
Preserved ejection fraction (≥50%) 78 (63.4) 278 (60) 296 (67.6) 0.044h 652 (63.7)
Mid-range ejection fraction (40–49%) 25 (20.3) 92 (19.9) 78 (17.8) 195 (19)
Reduced ejection fraction (<40%) 20 (16.3) 93 (20.1) 64 (14.6) 177 (17.3)
CCI
Score 0 54 (43.9) 239 (51.6) 276 (63) <0.001h, i 569 (55.6)
Score 1 38 (30.9) 130 (28.1) 95 (21.7) 263 (25.7)
Score ≥2 31 (25.2) 94 (20.3) 67 (15.3) 192 (18.8)
Depression symptom severity (PHQ-9)
PHQ-9 score 12.5±5.2 8.5±3.4 2.2±1.4 <0.001h, i, j 6.3±4.8
One-year mortality
Deceasedd 7 (5.7) 15 (3.2) 6 (1.4) 0.021i 28 (2.7)
Depression and anxiety disorders (DSM-IV diagnoses)
Lifetime history of any depressive disorder 42 (34.1) 118 (25.5) 47 (10.7) <0.001h, i 207 (20.2)
Lifetime history of any anxiety disordere 50 (49) 97 (23.4) 42 (10) <0.001h, i, j 189 (20.2)
Depression treatment at baselinef
Any depression treatment 34 (27.6) 34 (7.3) 11 (2.5) 79 (7.7)
Only psychotherapyg 8 (6.5) 6 (1.3) 3 (<1%) 17 (1.7)
Only antidepressant medication 20 (16.3) 19 (4.1) 8 (1.8) 47 (4.6)
Psychotherapy and antidepressant medication 6 (4.9) 9 (1.9) 0 15 (1.5)
Other psychopharmacological treatmentf
Use of benzodiazepines 6 (4.9) 2 (0.4) 3 (0.7) 11 (1.1)
Values are presented as means ± SD or numbers (%). ACS, acute coronary syndrome; CCI, Charlson Comorbidity Index; DSM-IV, Diagnostic and Sta-
tistical Manual of Mental Disorders; LVEF, left ventricular ejection fraction; PHQ, Patient Health Questionnaire. 
a Values refer to overall comparisons. Significant p values (<0.05) are highlighted in bold. Significant post hoc comparisons are indicated by superscripts; 
p was set at <0.017 after Bonferroni correction. b 27 patients had missing data. c 13 patients had missing data. d In 3 patients, the vital status could not be as-
certained. e 89 patients had missing data. f Because of low numbers in each category, no statistical comparison was conducted. g 22 patients had missing data. 
h No depressive symptoms vs. elevated depressive symptoms (all p < 0.017). i No depressive symptoms vs. clinical diagnosis (all p < 0.017). j Elevated depres-
sive symptoms vs. clinical diagnosis (all p < 0.017).
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Patients without depressive
disorder but with elevated
depressive symptoms
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AHA: Carefully monitor for treatment adherence, drug efficacy and safety
AHA: Carefully monitor for treatment adherence, drug efficacy and safety
Fig. 1. Course of depression and steps of depression management according to the American Heart Association (AHA) and National 
Institute for Health and Care Excellence (NICE). * Patient Health Questionnaire (PHQ-9) item 9 ≤1; n = 12 missing data.




Prevalence of Clinical and Subclinical Depression at 
Baseline
According to the DSM-IV, 123 patients (overall 12%; 
18.3% of the women and 10.5% of the men) met the cri-
teria for any depressive disorder. Of those, 46 (37.4%) had 
an MDD, 38 (30.9%) had dysthymia, and 39 (31.7%) had 
both; 463 patients (45.2%; 46.2% of the women and 45% 
of the men) had subclinical depression (elevated depres-
sive symptoms in the absence of a clinical depression di-
agnosis), and of those 69.8% were subthreshold depressed 
and 30.2% exhibited moderate to severe depressive symp-
toms. Forty-three percent had no signs of depression at 
baseline.
Depression Treatment at Baseline and during Follow-
Up 
The baseline depression treatment rates are displayed 
in Table 1. Of the follow-up sample (n = 837), a total of 
118 (14.1%) patients received psychotherapy and/or an-
tidepressant medication during any time point in the 12 
months (online suppl. Table 1). Fifty-four (6.5%) of the 
patients received continuous depression treatment at all 
3 time points.
Among patients with a depressive disorder (n = 123), 
34 (27.6%) were in treatment at baseline. Of the follow-up 
sample (n = 95 with a depressive disorder at baseline), 44 
(46.3%) received treatment during any time point in the 
12 months; 25 (26.3%) received continuous treatment at 
all 3 time points.
Mortality and Availability for Follow-Up
Of all 1,024 patients, 28 (2.7%) died within 12 months 
(for 3 patients, the vital status could not be ascertained). 
After adjustment for age, sex, and risk factors, any depres-
sive disorder and depression severity were associated 
with an increased risk of mortality (adjusted HR = 3.19; 
95% CI 1.32–7.69 for any depressive disorder, and ad-
justed HR = 1.09; 95% CI 1.02–1.16 for depressive symp-
toms [per unit increase], respectively). Depression treat-
ment was not included in the model because none of the 
patients under depression treatment died within 1 year.
One hundred fifty-nine (15.5%) patients were lost to 
follow-up. Compared to the study completers, these pa-
tients were significantly younger (58.9 ± 11 vs. 63.2 ± 9.8 
years; p < 0.001), exhibited more depressive symptoms at 
baseline (PHQ-9 score 6.9 ± 5.2 vs. 6.1 ± 4.7; p < 0.05), 
were more likely to have an ACS at baseline (49.7 vs. 
39.2%, p < 0.05), and had a lower LVEF (22.6 vs. 15.7% 
had a reduced ejection fraction < 40%; Mann-Whitney U 
test; p < 0.05).
Course of Depression among Different Depression 
Groups
Figure 1 displays the longitudinal course of depressive 
symptoms among different depression groups as well as 
recommended steps of depression care in line with the 
AHA (online suppl. Fig. 1a) and NICE (online suppl. 
Fig. 1b) guidelines. Overall, 57% exhibited at least mild 
depressive symptoms at baseline. More than 85% of the 
patients with a depressive disorder continued to have el-
evated depressive symptoms at both follow-up assess-
ments, with more than half of these reporting 
consistently moderate to severe symptoms. 
Of patients with initially elevated symptoms, 47% (n = 
174) continued to have persistent depressive symptoms 
over the course of 1 year and 27% (n = 101) were in remis-
sion. Among the group of patients with no signs of de-
pression, 72% (n = 267) remained persistently nonde-
pressed and 10% (n = 38) later developed elevated depres-
sive symptoms. Overall, the majority of patients under 
depression treatment at baseline (71%) were persistently 
depressed at both follow-ups (i.e., 73% of the patients in 
the group with subclinical depression and 90% of those 
with clinical depression).
Predictors of Persistent Depressive Symptoms during 
Follow-Up
Among patients with clinical depression, 85% exhib-
ited persistently elevated depressive symptoms during 
follow-up and only 5 patients were in remission. It was 
thus not possible to identify predictors of depression per-
sistence among this group. Nevertheless, we analyzed the 
course of depression symptoms by treatment status. As 
shown in online supplementary Figure 3, patients with 
continuous depression treatment across 12 months had 
the highest PHQ-9 scores compared to patients with in-
termittent treatment and patients with no treatment. In 
all groups, the mean PHQ-9 score was ≥10 at all time 
points. 
The adjusted OR for predictors of depression persis-
tence in patients with initially subclinical depression and 
those with no depression symptoms are presented in Ta-
ble 2. 
Among patients with subclinical depression at base-
line, the level of initial depressive symptoms, a history of 
depressive disorder, and anxiety disorder, respectively, 
significantly predicted depression persistence across 12 
months (all p < 0.05). Among initially nondepressed pa-
tients, elevated depressive symptoms at the 6- and 
12-month follow-up were associated with increased ini-
tial depressive symptoms, a history of depressive disor-
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der, a reduced LVEF, and the occurrence of an ACS at 
baseline (all p < 0.05). Whereas the rates of unstable an-
gina were similar in both groups, the rate of myocardial 
infarction was higher in patients with incident depressive 
symptoms than in persistently nondepressed patients 
(47.4 vs. 27.7%).
Depression Management Need within 1 Year
Figure 2 displays the expected depression manage-
ment need according to the AHA (online suppl. Fig. 1a) 
and NICE (online suppl. Fig. 1b) guidelines based on the 
longitudinal depression course in a sample of 1,024 hos-
pitalized CHD patients. While approximately half of all 
patients has no management need, around one third 
would require either initiation or adjustment of depres-
sion management. The exact management procedure ac-
cording to NICE depends on whether treatment is al-
ready implemented. Sixteen percent of all patients were 
lost to follow-up, and thus the depression management 
need is unknown in these patients. 
Table 2. Adjusted OR for persistently elevated depressive symptoms 6 and 12 months after hospitalization
Predictor OR 95% CI p
Patients with initially subclinical depression (elevated depressive symptoms) (n = 275); persistent depressive 
symptoms (n = 174) (vs. remitted depressive symptoms at 6 and 12 months)
Sex (female = 0, male = 1) 0.63 (0.27–1.49) 0.292
Age 0.99 (0.96–1.03) 0.654
Education 1.02 (0.53–1.95) 0.954
Partner status 1.18 (0.51–2.71) 0.697
Antidepressant treatment (absence = 0, presence = 1) 3.46 (1.15–10.41) 0.027
CCI
Score 0 Reference
Score ≥1 1.42 (0.74–2.73) 0.292
ACS (absence = 0, presence = 1) 0.95 (0.5–1.83) 0.882
LVEF
Preserved ejection fraction (≥50) Reference
Mid-range ejection fraction or reduced ejection fraction (<50) 1.27 (0.67–2.38) 0.465
Baseline PHQ-9 score 1.46 (1.27–1.69) <0.001
Lifetime history of depressive disorder (absence = 0, presence = 1) 2.41 (1.06–5.47) 0.035
Lifetime history of anxiety disorder (absence = 0, presence = 1) 2.64 (1.11–6.29) 0.029
Patients with initially no depressive symptoms (n = 305); incident depressive symptoms (n = 38) (vs. persis-
tently no depressive symptoms at 6 and 12 months)
Sex (female = 0, male = 1) 0.77 (0.24–2.48) 0.660
Age 1.00 (0.95–1.05) 0.877
Education 0.76 (0.31–1.84) 0.542
Partner status 2.67 (0.5–14.34) 0.251
Antidepressant treatment (absence = 0, presence = 1) 1.19 (0.2–7.09) 0.847
CCI
Score 0 Reference
Score ≥1 2.5 (0.94–6.61) 0.065
ACS (absence = 0, presence = 1) 4.7 (1.87–11.84) 0.001
LVEF
Preserved ejection (≥50) Reference
Mid-range EF or reduced EF (<50) 0.4 (0.17–0.92) 0.032
Baseline PHQ-9 score 1.76 (1.24–2.48) 0.001
Lifetime history of depressive disorder (absence = 0, presence = 1) 5.65 (1.78–17.88) 0.003
Lifetime history of anxiety disorder (absence = 0, presence = 1) 2.85 (0.76–10.73) 0.121
ACS, acute coronary syndrome; CCI, Charlson Comorbidity Index; CI, confidence interval; LVEF, left 
ventricular ejection fraction; OR, odds ratio; PHQ, Patient Health Questionnaire.
The binary logistic regression models simultaneously included all of the listed predictors. For continuous 
variables, OR correspond to 1 unit increase. Significant p values (<0.05) are highlighted in bold.





In this consecutive cohort of hospital-treated CHD pa-
tients, elevated depressive symptoms at the time of hos-
pital treatment were prevalent and they were associated 
with an increased 12-month mortality risk. Among sur-
vivors, the rates of depression treatment were low and 
persistently elevated depressive symptoms were found in 
85% of patients with clinical depression, 47% of patients 
with subclinical depression, and 10% of patients with ini-
tially no depressive symptoms. Applying existing clinical 
recommendations [13, 14], one third of patients would 
need some form of depression management over the 
course of 1 year.
At hospitalization, 12% had a depressive disorder and 
45% had subclinical depression. These rates are higher in 
comparison to the general population [20, 21] and at the 
lower end of prevalence rates reported in other CHD 
samples, which range between 7 and 45% [3, 22–24]. In 
contrast to most studies with CHD patients, we defined 
clinical depression not only as MDD but also as dysthy-
mia, which is also common among CHD patients [25]. 
Dysthymia is the more chronic form of depression, which 
persists for at least 2 years with milder symptoms [14], is 
equally burdensome, and tends to progress to MDD [26].
Depressed patients were more likely to be female, be 
younger, be living without a partner, and have more co-
morbidities, which is known from other studies [3, 22]. 
Clinically depressed patients were more than 3 times 
more likely to have had a previous depressive disorder in 
their lifetime compared to patients without current de-
pressive symptoms. Our data also confirms previous 
findings that depression is a risk factor for mortality, in-
dependently of somatic comorbidity [4, 24]. This applies 
to both depressive symptoms and clinical depressive dis-
orders, which is noteworthy because few studies on de-
pression and mortality have assessed depression using a 
structured interview [27].
Depression treatment rates were insufficient; less than 







































Fig. 2. Depression status and depression management need within 1 year (n = 1,024). MDD, major depressive 
disorder.
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depression treatment, and only 26% received continuous 
treatment. Similar treatment rates were found in another 
CHD patient cohort [28] and in the general German pop-
ulation [29]. Poor recognition of depression by health-
care providers has previously been reported [30, 31], yet 
patients may also be responsible for poor treatment rates. 
In a series of community surveys, only an average of 65% 
of patients with MDD in high-income countries reported 
that they had a treatment need, and, among those, 22% 
did not initiate treatment [32].
The rates of depression persistence were high in our 
study; 85% of clinically depressed and 47% of subclini-
cally depressed patients reported elevated depressive 
symptoms at all time points. High levels of persistent de-
pression have previously been shown in patients after 
acute myocardial infarction [23, 33, 34]. In our sample, 
patients with a more severe depression were more likely 
to receive depression treatment; however, they were also 
more likely to have persistent depressive symptoms. Clin-
ically depressed patients who continuously received de-
pression treatment had the highest symptom burden at 
all time points. Similar findings have previously been re-
ported [35]. This might be an indication that antidepres-
sant treatment is not effective enough in usual care. Non-
response to depression treatment is a common phenom-
enon even in highly standardized randomized clinical 
trials, which typically exclude less adherent patients with 
comorbidities. Full remission is hard to achieve and in 
approximately two thirds of patients multiple treatment 
steps are needed [36]. Moreover, relapses are common, 
with the highest relapse rate among patients who need 
more treatment steps. 
Other potential risks after antidepressant therapy are 
discontinuation symptoms [37], which include physical 
reactions (like nausea or vertigo), sleep disturbances, 
and mood reactions (like anxiety). These also apply to 
newer-generation antidepressants such as selective se-
rotonin reuptake inhibitors (SSRI) and serotonin-nor-
epinephrine reuptake inhibitors [38–40]. It has been 
postulated that antidepressant medication could poten-
tially contribute to depression chronicity [37, 41]. Long-
term use of antidepressant medication is increasing [42] 
and might be associated with poorer depression out-
comes [43]. However, causal inferences from observa-
tional data should be made with caution. Importantly, 
the design of our study did not allow us to test this hy-
pothesis. 
In several meta-analyses, the efficacy/effectiveness of 
antidepressant medication and psychotherapy for reduc-
ing depressive symptoms in stable and acute CHD cases 
have been shown to be small to moderate [6, 44–47]. Re-
mission rates range between 26 and 69% [6, 36, 48] and 
response rates range between 43 and 67%, [6, 36] depend-
ing on measures and intervention. Improvements in 
health-related quality of life have been reported after psy-
chological interventions with mixed results concerning 
mental and/or physical components of quality of life [44]. 
In 2 antidepressant trials with cardiac patients (1 with 
citalopram and 1 with escitalopram), quality of life im-
proved significantly in the treatment group versus the 
placebo group [49, 50].
Several studies have investigated possible effects of 
antidepressant treatments on clinical outcomes and 
mortality in CHD patient samples. One recent meta-
analysis showed a benefit of psychological interventions 
on cardiac mortality – albeit from studies of mixed qual-
ity [44]. Possible cardiotoxic effects of antidepressants 
have been discussed. Evidence from a broad range of 
studies suggests that selective serotonin reuptake inhibi-
tors are relatively safe in cardiovascular patients or even 
beneficial with regard to mortality rates [51, 52] and car-
diac events [53]. In contrast, a recent observational study 
showed that the longer-term risk for major adverse car-
diac events might be increased for different types of an-
tidepressants (atypical, tricyclic, and some selective sero-
tonin reuptake inhibitors) [54]. However, due to a num-
ber of potential biases (e.g., confounding by indication), 
causal inferences from observational studies should be 
made with caution.
Importantly, RCT typically have strict inclusion/ex-
clusion criteria (e.g., multimorbid patients are excluded 
and those with a poor antidepressant treatment response 
in the past) and thus comparisons with patients who re-
ceive depression treatment in usual care settings should 
be made with caution. A recent study using registry data 
from 4,062 patients showed that patients with treated de-
pression had the same mortality risk as patients without 
depression, whereas untreated patients had a higher mor-
tality risk [28]. In our study, we found that none of the 
patients in depression treatment died within 12 months. 
However, our sample was too small to test whether un-
treated depressed patients had an increased mortality 
risk.
What are the risk factors for persistent depression? 
Analyses on predictors of persistently elevated depressive 
symptoms showed that patients with subclinical depres-
sion who had a history of a depressive or an anxiety dis-
order were particularly at risk for persistent depressive 
symptoms, supporting recommendations to pay special 
attention to known depression or anxiety disorders [1, 13, 




14]. In patients who were initially nondepressed, a his-
tory of depression was also a predictor of incident depres-
sive symptoms during the 1-year follow-up. In addition, 
incident depression was more likely in patients with a 
lower LVEF and in patients who had an ACS at baseline. 
Our data indicates that it might primarily be acute myo-
cardial infarction which is the driving risk factor for inci-
dent depression; however, the sample size did not allow 
for a differential analysis of ACS type. 
Strengths and Limitations
The strengths of this study are its large sample size, the 
standardized diagnostic assessment of clinical depression 
according to DSM-IV criteria, 2 follow-up assessments, 
and few exclusion criteria to approximate a real-life 
healthcare setting for CHD patients. 
Our data does not provide information on the appro-
priateness of the depression treatments, recognition rates, 
treatment refusals, or reasons for treatment discontinua-
tions. Additionally, treatment effects are difficult to assess 
in usual care and the design of our study does not allow 
for causal conclusions. Moreover, antidepressant medi-
cation may not necessarily have been prescribed for de-
pression but also for sleep problems or anxiety disorders. 
Attrition was higher in patients with more severe depres-
sive symptoms; this could have resulted in underestimat-
ed rates of persistent depression.
Conclusions and Clinical Implications
This study confirms the high prevalence and increased 
mortality risk of depression in CHD patients in a real-
world, usual-care setting in a country with highly special-
ized care. Moreover, it demonstrates a lack of sufficient 
depression recognition and depression management. As-
sessing previous depressive or anxiety disorders may help 
to identify patients at an increased risk for persistent de-
pression, and heightened awareness should be exercised 
in relation to patients after an ACS. Overall, about one 
third of hospitalized CHD patients would require some 
form of depression management over the course of 1 year 
[13, 14]. The lowest level of management would be noti-
fication of the general practitioner and/or referral to a 
mental health specialist. Treatment response should be 
monitored and insufficient responses appropriately man-
aged. Collaborative care is a promising healthcare deliv-
ery model for patients with depression with and without 
a somatic illness [55–57], even for subthreshold depres-
sion [58]. Whether a systematic depression screening will 
result in improved depression outcomes remains to be 
studied. Particularly in view of the limited effects of anti-
depressant therapy on both mental health and cardiac 
prognosis, other possible targets of clinical management 
should be considered in CHD patients. Such targets might 
include chronic stress, demoralization, quality of life, 
well-being, illness behavior, and anxiety [59, 60]. These 
components may have an impact on cardiovascular prog-
nosis and interact with depression as well as its assess-
ment and treatment. Treatment of these targets might re-
sult in cardiovascular benefits [61]. In clinical practice, a 
wider range of psychosocial conditions should be consid-
ered.
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